AMRX Amneal Pharmaceuticals Inc. Class A

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Amneal to Report Third Quarter 2025 Results on October 30, 2025

BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at . Individuals may register for the webcast by clicking the link . To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this . The access code for the call is 272787. A replay of the conference call will be posted shortly after the call.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit  and follow us on .

Investor Contact

Anthony DiMeo

VP, Investor Relations



EN
30/09/2025

Underlying

AMRXAmneal Pharmaceuticals Inc. Class A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amneal Pharmaceuticals Inc. Class A

 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

Amneal Reports Fourth Quarter and Full Year 2025 Financial Results ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million; Adjusted EBITDA of $688 million...

February 27, 2026 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026. Launched in 1994, the S&P SmallCap 600 Index is one of the most widely followed benchmarks for U.S. small-capitalization equities. The index is commonly used by active managers and small-cap investors seeking exposure to companies that meet disc...

January 28, 2026 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal to Report Fourth Quarter and Full Year 2025 Results on February...

Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at . Individuals may register for the webcast by clickin...

January 27, 2026 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Pro...

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics Licensing Applications (BLAs) for Boncresa™ (denosumab-mobz), a b...

December 22, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single-...

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilize...

December 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch